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The amine-carboxyborane derivatives were shown to be effective antineoplastic/cytotoxic agents with selective activity against single-cell and solid
tumors derived from murine and human leukemias, lymphomas, sarcomas, and carcinomas. The agents inhibited DNA and RNA synthesis in prefer-
ence to protein synthesis in L1210 lymphoid leukemia cells. Inosine-monophospate dehydrogenase apparently is a target site of the compounds; simi-
lar effects on phosphoribosyl-pyrophosphate amido transferase, orotidine-monophosphate decarboxylase, and both nucleoside and nucleotide kinas-
es were observed. Deoxyribonucleotide pool levels were reduced in the cells; DNA strand scission was observed with the agents. In rodents, the
amine carboxyboranes were potent hypolipidemic agents, lowering both serum cholesterol and triglyceride concentrations, in addition to lowering
cholesterol content of very low-density lipoprotein and low-density lipoprotein (LDL) and elevating high-density lipoprotein (HDL) cholesterol concen-
trations. De novo regulatory enzymes involved in lipid synthesis were also inhibited (e.g., hypocholesterolemic 3-hydroxy-3-methyl-Coenzyme A reduc-
tase, acyl-Coenzyme A cholesterol acyltransferase, and sn-glycerol-3-phosphate acyltransferase). Concurrently, the agents modulated LDL and HDL
receptor binding, internalization, and degradation, so that less cholesterol was delivered to the plaques and more broken down from esters and con-
ducted to the liver for biliary excretion. Tissue lipids in the aorta wall of the rat were reduced and fewer atherosclerotic morphologic lesions were pre-
sent in quail aortas after treatment with the agents. Cholesterol resorption from the rat intestine was reduced in the presence of drug. Genetic hyper-
lipidemic mice demonstrated the same types of reduction after treatment with the agents. The agents would effectively lower lipids in tissue based
on the inhibition of regulatory enzymes in pigs. These findings should help improve domestic meat supplies from fowl and pigs. The amine-carboxy-
boranes were effective anti-inflammatory agents against septic shock, induced edema, pleurisy, and chronic arthritis at 2.5 to 8 mg/kg. Lysosomal
and proteolytic enzyme activities were also inhibited. More significantly, the agents were dual inhibitors of prostaglandin cyclooxygenase and
5-lipoxygenase activities. These compounds also affected cytokine release and white cell migration. Subsequent studies showed that the amine-
carboxyboranes were potent anti-osteoporotic agents reducing calcium resorption as well as increasing calcium and proline incorporation into mouse
pup calvaria and rat UMR-106 collagen. - Environ Health Perspect 102(Suppl 3):21-30 (1994)
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Introduction
The amine-borane derivatives were synthe-
sized as amine-, cyano- and carboxyboranes
(1-4); di- and tripeptides of boron ana-
logues of amino acids (5); aminomethyl-
phosphonate cyanoborane adducts (6,7);
tricyclohexyl- and triphenylphosphine-
boranes (8); metal complexes and salts of
substituted hydroborates (9); boron ana-
logues of phosphonoacetates (10); hetero-
cyclic amine-carboxyboranes (11);
hydropolyborates (12), boron analogs of
choline and thiocholine (13); and
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2'-deoxynucleoside and nucleotide cyano-
boranes (14-16). All of these derivatives
demonstrated a variety of pharmacologic
activities. This discussion will concentrate
on the amine carboxyboranes and their
esters as representative therapeutic agents
ofthe entire boron group ofchemicals.
Initially, the amine-carboxyborane deriv-
atives were shown to be nontoxic in CF,
male mice when administered at 20, 50, or
100 mg/kg/day, intraperitoneally (ip), for
7 days (17). Variables measured were sur-
vival, total body weight, daily food con-
sumption, individual body weight, clinical
chemistry values, hematopoietic values, and
histologic evaluations of major organs.
LD50 values (dose required for 50% deaths)
ofthese compounds were between 1 and 2
g/kg, ip, in mice.
Then we examined these compounds for
antineoplastic activity (9). Because these
amine carboxyboranes were similar in
structure and size to endogenous interme-
diary substrates, they could be functioning
as antimetabolites (e.g., of amino acids or
betaine). Once they are taken up into cells,
a second mechanism of action is neutron
capture. An identified organ or foci of tis-
sues can be irradiated with neutrons,
whereupon the boron atom will capture a
neutron and decay to emit an alpha parti-
cle. This process causes local tissue damage
and cell death. In vivo these boron deriva-
tives have demonstrated strong activity
against Ehrlich ascites carcinoma growth,
Lewis lung carcinoma, and B,6 melanoma.
Marginal activity against P388 lymphocytic
and L1210 lymphoid leukemia cells was also
demonstrated. Selected compounds (Table
1) were tested for cytotoxicity against
murine and human tissue culture cells.
These compounds were active against the
growth of single tumor cells (e.g., L1210,
Tmolt3, and HeLa-S3; Table 1). Selectivity
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Table 1. Effects of amine boranes on murine and human tissue cell growtha.
ED50value (pg/ml)
Murine human
SW480 Lung- HeLa-S3 KB
Compound L1210 P388 Tmolt3 colon bronchogenic uterine Glioma naso-pharyngeal Osteo-sarcoma
(C6H5)3PBH2COOH 2.97 2.89 2.76 6.57 3.64 -
C6H33N(CH3)2BH2COOH 4.80 13.51 3.63 2.25 7.43 2.50 2.89 7.89 2.47
C,8H37N(CH3)2BH2COOH 1.74 4.49 1.41 6.60 9.60 2.25 7.84 4.05 3.12
(CH3)2NHBH2COOCH 5.48 10.11 4.70 1.82 4.00 2.70 1.56 4.46 2.15
(CH3)3NBH2COOCH3 1.02 11.11 2.30 5.87 4.24 2.73 5.01 8.45 5.13
CH3NH2BH2COOH 4.01 14.61 4.72 0.84 4.35 3.92 6.74 4.32 5.21
CH3CH2NH2BH2COOH 3.87 3.12 4.71 2.19 7.25 1.63 6.96 3.67 5.45
(CH3)2NHBH2COOH 2.72 12.86 5.76 2.25 4.89 2.67 2.62 4.59 5.27
5FU 1.41 3.72 2.14 3.09 3.69 2.47 1.28 1.25
Ara C 2.76 4.23 2.67 3.42 4.60 2.13 1.88 2.84
Hydrox-urea 2.67 3.18 4.74 7.37 1.96 2.27 5.29 7.59
VP16 0.64 1.16
aCytotoxicity of specific amine boranes (first 8 listed) was determined in tissue culture cells grown by literature techniques. ED50 (effective dose, 50%) values were deter-
mined forL1210, P388, Tmolt3, and HeLa-S3 tumor cells by counting single cells in a hemocytometer using trypan blue exclusion (n=5). Solid tumor cell growth was determined
with crystal violet/MeOH in 96 well plates that were read with a Molecular Devices Softmax at 580 nm. SignificantED5 values were less than 4pg/ml.
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Figure 1. DNA synthesis in L,210 cells. Effects of com-
pounds 1, 5, and 7 at 0, 10, 25, 50, and 100 pM after
60-min incubations on 106 L120 lymphoid leukemia
cells. 3H-thymidine incorporation into DNA.
was demonstrated by the compounds
against the growth of cells derived from
solid tumors [e.g., SW480 adenocarcino-
ma of the colon, glioma, or osteosarcoma
(9)]. Modification ofstructures, including
a heterocyclic ring (11) or a 2'-deoxyri-
bonucleoside (14,15), enhanced the anti-
neoplastic activity.
The L1210 cell line was selected to investi-
gate the mode of action for these deriva-
tives because its properties are well estab-
lished as a laboratory tumor cell model.
DNA and RNA syntheses were inhibited
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Figure 2. RNA and protein synthesis in L,2,0 cells.
Effects of compounds 1, 5, and 7 at 0, 10, 25, 50, and
100 pM after 60 min incubations on 106 L12l0 lymphoid
leukemia cells. 3H-Uridine incorporation into RNA and
3H-leucine incorporation into protein.
in a concentration dependent manner
(Figures 1, 2) and protein synthesis was
sometimes marginally inhibited. The de
novo nucleic acid synthesis of purines was
reduced by the agents specifically at phos-
phoribosyl pyrophosphate (PRPP)-amido
transferase and inosine monophosphate
(IMP) dehydrogenase enzyme sites, the reg-
ulatory sites in the pathway (Figure 3).
Apparently, the latter enzyme is a major tar-
get of the amine-cyanoborane derivatives.
Pyrimidine de novo synthesis was also
inhibited by compounds 1 and 7 (Figure
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Figure 3. Purine synthesis in L120cells. Effects of com-
pounds 1, 5, and 7 at 100 pM after 60-min incubations
on L1210 lymphoid leukemia cells. De novo purine syn-
thesis as 4C-glycine incorporation, phosphoribosyl
pyrophosphate, PRPP amido transferase, and inosine
monophosphate, IMP dehydrogenase activities.
4). Orotidine monophosphate (OMP)
decarboxylase was the major site at which
the agents functioned as inhibitors.
Nucleoside and nucleotide kinase activities
were also inhibited (Figure 5). Ribonucleo-
side reductase, dihydrofolate reductase,
DNA polymerase ax and topoisomerase II
activities were inhibited by specific boron
agents, but not by all of the agents.
Inhibition was dependent on the substitut-
ed moieties of the basic structure of the
amine-carboxyboranes. This class of boron
derivatives reduced the deoxyribonucleotide
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Figure 4. Pyrimidine synthesis in L121 cells. Effects of
compounds 1, 5, and 7 at 100 pM after 60-min incuba-
tions on L1210 lymphoid leukemia cells. De novo pyrimi-
dine synthesis as 14C-formate incorporation, carbamyl
phosphate synthetase, aspartate transcarbamylase,
orotidine monophosphate, OMP decarboxylase, and
thymidylate synthetase activities.
[d(NTP)] pools after incubation for 60
min at 100 pM (Figure 6). L1210 deoxyri-
boguanosine triphosphate, deoxyribocyto-
sine triphosphate, and deoxyribothymidine
triphosphate pools were reduced, whereas
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Figure 5. Enzyme activities in L1210 cells. Effects of
compounds 1, 5, and 7 at 100 pM after 60-min incuba-
tions on L1210 lymphoid leukemia cells. Thymidine
kinase, TMP kinase, TDP kinase, dihydrofolate reduc-
tase, and ribonucleoside reductase activities.
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Figure 6. d(NTP) pools in L1210 cells. Effects of com-
pounds 1, 5, and 7 at 100 pM after 60 min incubations
on L1210 lymphoid leukemia cells. Deoxyribonucleotide,
d(NTP) pools, including deoxyriboadenosine triphos-
phate, d(ATP), deoxyriboguanosine triphosphate, d(GTP),
deoxyribocytosine triphosphate, d(CTP), and deoxyriboth-
ymidine triphosphate, d(TTP) determinations.
deoxyriboadenosine triphosphate pools
were not as markedly affected. These
reductions alone would account for the
inhibition of DNA synthesis and cell
growth. The inhibition of de novo purine
synthesis by the agents is also reflected in
the reduction of the d(NTP) pool levels.
Further studies with calf thymus DNA in
vitro indicated that these compounds did
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Figure 7. DNA strand scission. Effects of compounds
1, 5, and 7 at 100 pM after 24-hr L1210 lymphoid
leukemia DNA strand scission.
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Figure 8. Mouse serum lipid levels. Effects of com-
pounds 1 to 8 at 20mg/kg/day, ip on CF mouse serum
cholesterol andtriglyceride concentrations 9 and 16.
not act as intercalator binding between the
bases of DNA or crosslinks between the
two strands of DNA. However, these
amine cyanoboranes did cause DNA strand
scission in L1210 cells after 24-hr incubation
at 100 pM (Figure 7).
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Figure 9. Rat serum lipids. Effects ofcompounds 5 and
7 at 8 mg/kg/day, orally on Sprague-Dawley rat
serum cholesterol and triglyceride concentrations on
days 7 and 14.
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Figure 10. Rat enzyme activities in vivo. Effects of
compound 5 at 8 mg/kg/day, orally on Sprague-
Dawley rat liver de novo enzyme activites on day 14.
Crossover in pharmacologic activity
between antineoplastic, antibacterial, anti-
viral, immunomodulatory, and antiinflam-
matory activities is well documented for a
number of chemically unrelated agents.
Currently, evidence is accumulating to sup-
port the contention of a crossover between
antineoplastic and hypolipidemic activity.
For example, compactin, a hypocholes-
terolemic 3-hydroxy-3-methylglutaryl-
Coenzyme A reductase (HMG-CoA reduc-
tase) inhibitor, inhibited DNA synthesis in
L929 tumor cells (18). Similar types of
crossover in activity between the 2,3-dihy-
drophthalazine-1,4-dione (19), sesquiter-
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Figure 11. Rat liver lipids. Effects of compounds 5 and
7 at 8 mg/kg/day, orally after 14 days on Sprague-
Dawley rats. Liver lipid concentrations.
Figure 12. DNA strand scission. Effects of compounds
5 and 7 at 8 mg/kg/day, orally after 14 days on
Sprague-Dawley rats. Aorta wall high density lipid con-
centrations.
pene lactone (20), and benzohydroxamic
acids (21) are known to occur. When the
amine carboxyboranes were examined for
hypolipidemic activity in CF, male mice,
both serum cholesterol (18-48%) and
triglyceride (19-77%) levels were reduced
after 16 days at 20 mg/kg/day, ip (22)
(Figure 8). When tested in Sprague-
Dawley rats at 8 mg/kg/day orally for 14
days, both serum cholesterol (-35%) and
triglyceride levels (32-58%) were reduced
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Figure 13. Rat feces lipids. Effects of compounds 5
and 7 at 8 mg/kg/day, orally after 14 days on
Sprague-Dawley rats. Fecal lipid concentrations.
Figure 14. Bile excretion. Effects of compounds 5 and
7 at 8 mg/kg/day, orally after 14 days on Sprague-
Dawley rats. Bile lipids.
significantly (Figure 9). The reduction in
lipids probably is the result of the amine
carboxyboranes' inhibition of key enzyme
activities in the de novo synthesis ofcholes-
terol, i.e., HMG-CoA reductase, acetyl-
CoA synthetase, fatty acids [i.e., citrate
lyase, and triglycerides, such as sn-glycerol-
3-phosphate acyltransferase and phos-
phatidylate phosphohydrolase (Figure 10)].
Rat tissue lipids, specifically cholesterol
concentrations, were reduced in the liver
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Figure 15. Chylomicron lipids. Effects of compounds
and 7 at 8 mg/kg/day, after 14 days orally on
Sprague-Dawley rat. Chylomicron lipid concentrations.
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Figure 16. VLDL lipids. Effects of compounds 5
and 7 at mg/kg/day, after 14 days orally on
Sprague-Dawley rat. VLDL concentrations.
after 14 days administration (Figure I 1)
and in the aorta wall (Figure 12), but not
in the small intestine (data not shown).
On the other hand, lipids, particularly
cholesterol and triglycerides, were
increased in the feces (Figure 13) and bile
(Figure 14). Further studies in rats showed
that the serum lipoprotein lipid content
was altered by drug treatment (Figures
15-18). Compound 5 was effective in low-
ering cholesterol content in the chylomi-
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Figure 18. HDL lipids. Effects of compounds 5 and 7 at
8 mg/kg/day, after 14 days orally on Sprague-Dawley
rat. HDL concentrations.
cron, very low-density (VLDL) and low-
density lipoprotein (LDL) fractions, while
elevating the cholesterol content in the
high-density lipoprotein (HDL) fraction.
The magnitude ofincrease in HDL choles-
terol was far superior to that of today's
clinically used agents. Triglycerides were
reduced in the chylomicron, VLDL, and
LDL fractions.
Figure 20. LDL degradation. Effects of compound 5 at
5, 10, 25, and 50 pM on activities in human liver and
fibroblasts, rat aorta and small intestinal mucosa, and
mouse macrophages after 5 hr. LDL degradation.
The ideal clinical hypolipidemic agent
should lower VLDL cholesterol content,
since this is the means by which cholesterol
is delivered to peripheral tissues, including
the aorta plaques. In patients with athero-
sclerosis, the LDL cholesterol concentra-
tion is high and the HDL cholesterol
oncentration is low. An effective hypolipi-
demic agent must reverse this ratio.
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Figure 17. LDL lipids. Effects of compounds 5 and 7 at
8 mg/kg/day, after 14 days orally on Sprague-Dawley
rat. LDL concentrations.
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Figures 19. LDL receptor binding. Effects of compound
5 at 5, 10, 25, and 50 pM on activities in human liver
and fibroblasts, rat aorta and small intestinal mucosa,
and mouse macrophages after 5 hr. LDL receptor activi-
ty and internalization.
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Figure 21. HMG-CoA reductase. Effects of compound 5
at 5, 10, 25, and 50 pM on activities in human liver and
fibroblasts, rataortaand small intestinal mucosa,and mouse
macrophagesafter5hr. HMG-CoA activity.
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Figure 22. ACAT activity. Effects of compound 5 at 5,
10, 25, and 50 pM on activities in human liver and
fibroblasts, rat aorta and small intestinal mucosa, and
mouse macrophages after 5 hr. ACAT activity.
Reversing the LDL/HDL cholesterol ratio
has been shown to protect man from
myocardial infarctions. The HDL fraction
is responsible for the uptake offree choles-
terol from peripheral cells (including aorta
plaques) and conducting cholesterol to the
liver for metabolism to cholic acid followed
by excretion in the bile.
Because modulations of the serum
lipoprotein fractions were favorable for
treatment of atherosclerosis, we initiated
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Figure 23. HDL receptor binding. Effects of compound
5 at 5, 10, 25, and 50 pM on activities in human liver
and fibroblasts, rat aorta and small intestinal mucosa,
and mouse macrophages after 5 hr. HDL receptor activ-
ity and internalization.
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Figure 24. HDL degradation. Effects of compound 5 at
5, 10, 25, and 50 pM on activities in human liver and
fibroblasts, rat' aorta and small intestinal mucosa, and
mouse macrophages after 5 hr. HDL degradation.
studies to understand further the agents'
effects on cellular lipid regulation (23).
LDL receptors are located on peripheral
cells which bind with high affinity to ape-B
lipoproteins. LDL cholesterol complexes
are taken up by the cell and merge with
lysosomal vesicles from which hydrolytic
enzymes are released. These enzymes digest
the complex and release free cholesterol.
These LDL receptors regulate the activities
of HMG-CoA reductase, acyl-CoA choles-
terol acyl transferase (ACAT), and choles-
terol 7at hydrolase. We found the amine
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Figure 25. Effects of compound 5 on Sprague-Dawley
rat in situloop resorption of cholesterol.
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Figure 26. Effects of amine borane derivatives at 8
mg/kg/day, orally after 8 weeks on quail atherogenic
scores and serum cholesterol concentrations.
carboxyboranes caused a decrease in LDL
receptor binding of '25I-LDL and its inter-
nalization (Figure 19). Further, the degra-
dation of the LDL-cholesterol complexes
was reduced, whether the complex entered
the cell through the high-affinity transport
mechanism or a nonreceptor transport
process (Figure 20). The net effect was that
less free cholesterol was released in the cell.
Macrophages, as scavenger mechanisms,
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Figure 27. In vivo activity in mice. Effects of amine
carboxyboranes at 8 mg/kg, ip on antiinflammatory
tests. Septic shock, Winter's induced edema, writhing,
and tail flick reflex.
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Figure 28. Mouse sponge evaluation: PMNs Flux
(MPO). Effects of amine carboxyboranes at 8 mg/kg,
ip, on antiinflammatory tests. PMN MPO activity flux
into mouse sponges, SC at 6 and 24 hr.
were responsible for the uptake ofacetyl-
LDL and P-VLDL to clear hyperlipidemic
lipoproteins from the plasma and tissues.
Tissue culture studies showed the agents
accelerated the uptake and degradation of
lipoproteins by the macrophages (Figure
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Figure 30. Macrophage enzyme activities. Fifty percent
inhibition of enzyme activity (IC50) values of amine car-
boxyboranes after 60 min. Effects on mouse
macrophage cathepsin, acid phosphatase, aryl sulfa-
tase, prostaglandin cyclooxygenase, typsin, and elas-
tase activities.
19). Liver and aorta HMG-CoA reductase
activity was inhibited by compound 5 in a
concentration-dependent manner. How-
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Figure 32. TNF-a release from [PS-induced
mnacrophage s. Effects of amine carboxyboranes at sev-
eral concentrations on cytokines. TNF-ax levels from
[PS-induced mouse IC-21 macrophages at 1o-6, 10-5
and 10-4 M concentrations.
ever, HMG-CoA reductase activity in small
intestinal mucosa, fibroblasts, and
macrophages was not reduced (Figure 21).
Inhibition of the activity of the ACAT
enzyme (the enzyme that converts choles-
terol to cholesterol esters, after treatment
with amine-carboxyboranes [Figure 22])
should reduce plaque growth because
deposition of cholesterol esters is related
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Figure 29. Mouse sponge evaluation: macro-
phage/monocyte flux (NAG). Effects of amine car-
boxyboranes at 8 mg/kg, ip, on antiinflammatory tests.
Macrophage/monocytes (NAG) flux into mouse
sponges, sc on days 5 and 9.
Figure 31. Be Sal osteoporotic cells enzyme activities.
Fifty percent inhibition of enzyme activity (IC50) values
of amine carboxyboranes after 60 min. Be Sal human
osteoporotic cellscathepsin, acid phosphatase, aryl sul-
phatase, prostaglandin cyclooxygenase, trypsin, and
elastase activities.
Compound
Figure 33. lI-1 Release from LPS-induced macrophages.
Effects of amine carboxyboranes at several concentra-
tions on cytokines. Il-1 release from LPS-induced IC-21
LPS-induced macrophages at 101 M.
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Figure 34. 11-2 and TNF-a in plasma from LPS-induced
CF-1 mice. Effects of amine carboxyboranes at several
concentrations on cytokines. Plasma tumor necrosis
factor (TNF-a) and 11-2 levels 90 min after lPS-induc-
tion in CFI mice treated 2 hr prior to LPS with amine
carboxyboranes at 8 mg/kg ip.
directly to plaque size. This process increas-
es with age of the individual and with
hyperlipidemic disease states. Activation of
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Figure 36. Calcium uptake by rat UMR-106 cells.
4"Calcium uptake of rat UMR-106 and IC-21
macrophage osteosarcoma cells from 5 x 10-7 to 5 x
101 M concentrations of amine carboxyboranes.
neutral cholesterol ester hydrolase activity
by the agents (data not shown), should
increase the breakdown ofcholesterol esters
in fibroblasts and small intestinal mucosa
cells. This would free cholesterol to attach
itself to HDL for transport from the arteri-
al plaque. Studies using human cultured
liver cells demonstrated that the agents
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Figure38. Proline incorporation by UMR-106 cells. 3H-
proline incorporation into collagen in presence of
amine carboxyboranes at 1, 10, and 100 pM. Rat UMR-
106 cells osteosarcoma.
accelerated high-affinity binding of HDL
via serum lipoprotein apoproteins Apo E
and Apo AT (Figure 23), which would
cause clearance of cholesterol from the
serum compartment. However, HDL
binding and degradation in other cells was
decreased (Figure 24). Indeed, in vivostud-
ies demonstrated fewer lipids in the rat
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Figure 35. Bone calcium resorption in rat pup calvaria
cultures. Bone 'calcium resorption of mouse pup cal-
vana bone at 10W to 101 M concentrations of amine
carboxyboranes.
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Figure 37. Proline incorporation: pupcalvaria. 3H-proline
incorporation into collagen in presence of amine carb-
oxyboranes at 1, 10, and 100 pM. Mouse CF1 pup cal-
varia bone.
Concentration (M)
Figure 39. Percent increase in cellular collagen. 3H-pro-
line incorporation into collagen in presence of amine
carboxyboranes at 1, 10, and 100 pM. Intracellular
increase in 3H-proline incorporation into collagen in rat
UMR-106 cells.
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aorta wall and more lipid excretion in the
bile, suggesting that the drugs accelerated
the HDL cholesterol reverse transport
process.
The trimethylamine-carboxyborane
derivative 5 accelerated cholesterol, triglyc-
eride and neutral lipid excretion into the
bile (Figure 14). Furthermore, the agent
increased the bile flow by 48%. Individual
bile acids demonstrated different concen-
trations after drug treatment; however,
there was no evidence that the agent
induced lithogenic effects like many
hypolipidemic agents. In situ rat intestinal
loop studies showed that agent 5 interfered
with cholesterol absorption/reabsorption
from the gut (Figure 25); however, it had
no effect on cholic acid reabsorption (data
not shown). This property of the agent
would also account for the observed reduc-
tion ofserum cholesterol over time.
In quail, treatment with amine-car-
boxyborane derivatives for 8 weeks reduced
serum cholesterol concentrations and num-
bers of atherosclerotic lesions in the aorta
(Figure 26). Some ofthe boron derivatives
ofthis chemical class should be effective in
reducing tissue lipids. These agents were
effective in the treatment ofgenetic hyper-
lipidemic, normalogenic and hypolipidem-
ic diseased mice, lowering lipid concentra-
tions in an analogous manner, as indicated
in the CF1 mouse and rat studies. Further
studies have indicated that the activities of
the same lipid regulatory enzymes in
miniature pig liver was inhibited by com-
pound 5, which suggests that the com-
pounds may be useful in agriculture in
improving the quality ofthe meat products
from domestic animals (24).
Another area where these compounds
have demonstrated good pharmacologic
activity is as antiinflammatory agents.
These agents were particularly useful in the
inhibition of induced edema, reduction of
local pain associated with inflammation,
and inhibition of centrally induced pain
(25) (Figure 27). But more important, the
agents protected against septic shock from
lipopolysaccharides (LPS) better than any
tested commercial agent. Selected agents
were also demonstrated to be effective
against chronic induced arthritis in rats at
2.5 mg/kg/day and active against pleurisy
in rats. Subcutaneous implantation of
sponges containing LPS (26) in mice
showed that agents blocked PMN
myeloperoxidase (MPO) activity's (Figure
28) and macrophage/monocyte N-acetyl-
glucosaminidase (NAG) activity's (Figure
29) migration to the inflammation sites.
These derivatives inhibited the activities of
lysosomal enzymes from a number of tis-
sues [e.g., PMNs, hepatocytes, and leuko-
cytes, with the concentration necessary for
50% inhibition of enzyme activity (IC50
value) in the range of 10-6M (Figures 30,
31)]. Although another characteristic of
these agents is their potent inhibition of
trypsin, elastase, and neutral cathepsin
activities, in our hands they were less
potent inhibitors ofcollagenase type I and
II activities with IC50 values from 10- to
10-5M (data not shown ). The agents
proved to be dual inhibitors of
prostaglandin cyclo-oxygenase and 5'-
lipoxygenase (27,28), with IC50 values in
the range of 10-6M. IC-21 macrophages
incubated with the agents secreted less
interleukin-1 (Il-1) and tumor necrosis fac-
tor-a (TNFa) cytokines (Figures 32,33).
However, after treatment with the agents at
8 mg/kg in mice in vivo 11-2 concentra-
tions were low in the blood and TN-a was
high (Figure 34). This relationship
between high amounts ofTNF-a in bacte-
rial or malarial infections and septic shock
is not unique. The deleterious effects nor-
mally attributed to TNF--a (e.g., cachexia
and endotoxic shock) may be incorrect.
Rather, deleterious effects may be the result
of other concurrently released cytokines,
like 11-6 or 11-8, and not TNF-a.
Examination of the derivatives for their
ability to block calcium resorption as anti-
osteoporotic agents was our next priority.
We first demonstrated that inorganic calci-
um, phosphorus, and hydroxyproline were
low in the urine but high in the blood
after 21-day treatment at 8 mg/kg/day in
mice. Four-day-old rat pup calvaria bone
exchanged less calcium to the medium in
the presence ofdrug from 10- to 10-4M
for 48 hr (29) (Figure 35). In rat UMR-
106 cultured osteosarcoma cells, calcium
resorption was blocked by the agent (30).
These derivatives were more active than
calcitonin and the bis-phosphate standard
in blocking calcium resorption.
Concurrent incorporation of calcium into
the cell collagen was increased in rat
UMR-106 cells, IC-21 macrophages, and
Be Sal human osteoporosis cells in the
presence of the agents (Figure 36). In
addition, an increase in labeled collagen
incorporation into cellular collagen was
also observed in these cells as well as in the
pup calvaria cultures (Figure 37) and
UMR-106 cells (Figure 38). The exchange
ofproline to the medium over the next 48
hr was reduced significantly in the pres-
ence ofdrugs (Figure 39). In a lactating rat
model in which rats were dosed orally for
14 days at 8 mg/kg/day, the amine
boranes increased bone volume, weight,
density, and ash weight, while elevating
bone and serum calcium levels. In conclu-
sion, the amine-carboxyborane derivatives
demonstrated promise as therapeutic
agents for a number ofdisease states.
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